The possibility of preparation of ophthalmic drug delivery systems using compressed anti-solvent technology was evaluated. Eudragit RS 100 and RL 100 were used as drug carriers, acetazolamide was the model drug processed. Compressed anti-solvent experiments were carried out as a semi-continuous or a batch operation from a liquid solution of polymer(s) + solute dissolved in acetone. Both techniques allowed the recovery of composite particles, but the semi-continuous operation yielded smaller and less aggregated populations than the batch operation. The release behaviour of acetazolamide from the prepared microparticles was studied and most products exhibited a slower release than the single drug. Moreover, the release could be controlled to some extent by varying the ratio of the two Eudragit used in the formulation and by selecting one or the other anti-solvent technique. Simple diffusion models satisfactorily described the release profiles. Composites specifically produced by semi-continuous technique have a drug release rate controlled by a diffusion mechanism, whereas for composites produced by the batch operation, the polymer swelling also contributes to the overall transport mechanism. © 2006 Elsevier B.V. All rights reserved.

The possibility of preparation of ophthalmic drug delivery systems using compressed anti-solvent technology was evaluated. Eudragit RS 100 and RL 100 were used as drug carriers, acetazolamide was the model drug processed. Compressed anti-solvent experiments were carried out as a semi-continuous or a batch operation from a liquid solution of polymer(s) + solute dissolved in acetone. Both techniques allowed the recovery of composite particles, but the semi-continuous operation yielded smaller and less aggregated populations than the batch operation. The release behaviour of acetazolamide from the prepared microparticles was studied and most products exhibited a slower release than the single drug. Moreover, the release could be controlled to some extent by varying the ratio of the two Eudragit used in the formulation and by selecting one or the other anti-solvent technique. Simple diffusion models satisfactorily described the release profiles. Composites specifically produced by semi-continuous technique have a drug release rate controlled by a diffusion mechanism, whereas for composites produced by the batch operation, the polymer swelling also contributes to the overall transport mechanism. © 2006 Elsevier B.V. All rights reserved.

Cobalt compounds of the general formula [COX2(alpha-diimine)], where X = Cl or I and the alpha-diimines are 1,4-diaryl-2,3-dimethyl-1,4-diaza-1,3-butadiene (Ar-DAB) and bis(aryl)acenaphthenequinonediimine (Ar-BIAN) were synthesized by the direct reaction of the anhydrous cobalt salts CoCl2 or CoI2 and the corresponding alpha-diinline ligand in dried CH2Cl2. The synthesized compounds are [Co(Ph-DAB)Cl-2] (1a), [Co(o,o',p-Me3C6H2-DAB)Cl-2] (1b), and [Co(o,o'iPr(2)C(6)H(3)-DAB)Cl-2] (1c) with the ligands Ar-DAB, and also [Co(o,o',p-Me3C6H2-BIAN)I-2] (2'b) with the ligand Ar-BIAN. The crystal structures of all the compounds were solved by single-crystal X-ray diffraction. In all cases the cobalt atom is in a distorted tetrahedron, which is built up of two halide atoms and two nitrogen atoms of the alpha-dimune ligand. X-band EPR measurements of polycrystalline samples performed on compounds 1b, 1c, and 2'b indicate a high-spin Col, ion (S = 3/2) in an axially distorted environment. Single-crystal EPR experiments on compounds 1b and 1c allowed us to evaluate the orientation of the g tensor in the molecular frame. (c) Wiley-VCH Verlag GmbH & Co.

n/a

n/a

n/a

n/a